Show simple item record

dc.contributor.authorAbugattas, J*
dc.contributor.authorLlacuachaqui, M*
dc.contributor.authorAllende, Y Sullcahuaman*
dc.contributor.authorVelásquez, A Arias*
dc.contributor.authorVelarde, R*
dc.contributor.authorCotrina, J*
dc.contributor.authorGarcés, M*
dc.contributor.authorLeón, M*
dc.contributor.authorCalderón, G*
dc.contributor.authorde la Cruz, M*
dc.contributor.authorMora, P*
dc.contributor.authorRoyer, R*
dc.contributor.authorHerzog, J*
dc.contributor.authorWeitzel, J N*
dc.contributor.authorNarod, S A*
dc.date.accessioned2016-05-23T16:20:52Zes_PE
dc.date.available2016-05-23T16:20:52Zes_PE
dc.date.issued2015-10es_PE
dc.identifier.citationPrevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Peru. 2015, 88 (4):371-5 Clin. Genet.es_PE
dc.identifier.issn1399-0004es_PE
dc.identifier.pmid25256238es_PE
dc.identifier.doi10.1111/cge.12505es_PE
dc.identifier.urihttp://hdl.handle.net/10757/610590es_PE
dc.descriptionEl texto completo de este trabajo no está disponible en el Repositorio Académico UPC por restricciones de la casa editorial donde ha sido publicado.es_PE
dc.description.abstractThe prevalence of BRCA1 and BRCA2 mutations among breast cancer patients in Peru has not yet been explored. We enrolled 266 women with breast cancer from a National cancer hospital in Lima, Peru, unselected for age or family history. DNA was screened with a panel of 114 recurrent Hispanic BRCA mutations (HISPANEL). Among the 266 cases, 13 deleterious mutations were identified (11 in BRCA1 and 2 in BRCA2), representing 5% of the total. The average age of breast cancer in the mutation-positive cases was 44 years. BRCA1 185delAG represented 7 of 11 mutations in BRCA1. Other mutations detected in BRCA1 included: two 2080delA, one 943ins10, and one 3878delTA. The BRCA2 3036del4 mutation was seen in two patients. Given the relatively low cost of the HISPANEL test, one should consider offering this test to all Peruvian women with breast or ovarian cancer.
dc.language.isoenges_PE
dc.publisherJohn Wiley & Sons, Inc.es_PE
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/25256238es_PE
dc.rightsinfo:eu-repo/semantics/embargoedAccesses_PE
dc.sourceUniversidad Peruana de Ciencias Aplicadas (UPC)es_PE
dc.sourceRepositorio Académico - UPCes_PE
dc.subjectBRCA1es_PE
dc.subjectBRCA2es_PE
dc.subjectPerues_PE
dc.subjectBreast canceres_PE
dc.subjectHereditaryes_PE
dc.titlePrevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Peru.es_PE
dc.typeinfo:eu-repo/semantics/articlees_PE
dc.identifier.journalClinical genetics (Clin Genet.)es_PE
dc.description.peer-reviewRevisión por pareses_PE
dc.contributor.emailsteven.narod@wchospital.caes_PE
html.description.abstractThe prevalence of BRCA1 and BRCA2 mutations among breast cancer patients in Peru has not yet been explored. We enrolled 266 women with breast cancer from a National cancer hospital in Lima, Peru, unselected for age or family history. DNA was screened with a panel of 114 recurrent Hispanic BRCA mutations (HISPANEL). Among the 266 cases, 13 deleterious mutations were identified (11 in BRCA1 and 2 in BRCA2), representing 5% of the total. The average age of breast cancer in the mutation-positive cases was 44 years. BRCA1 185delAG represented 7 of 11 mutations in BRCA1. Other mutations detected in BRCA1 included: two 2080delA, one 943ins10, and one 3878delTA. The BRCA2 3036del4 mutation was seen in two patients. Given the relatively low cost of the HISPANEL test, one should consider offering this test to all Peruvian women with breast or ovarian cancer.


This item appears in the following Collection(s)

Show simple item record